Welcome, Guest. Please login or register.
June 15, 2024, 12:46:51 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55127
  • Total Topics: 4851
  • Online Today: 109
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 94
Total: 94


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Post–Hep C Cure, Young Men Who Inject Drugs More Likely to Get Virus Again  (Read 8967 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
After people who inject drugs (PWID) are cured of hepatitis C virus (HCV), young men in particular have a higher rate of reinfection with the virus. Consistent use of medication-assisted treatment (MAT) for opioid use disorder, however, can apparently greatly mitigate the reinfection risk among PWID.

These are the findings of a Canadian study presented by Naveed Janjua, MBBS, of the British Columbia Centre for Disease Control at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases, in Boston this month.

Janjua and his colleagues analyzed data from the British Columbia Hepatitis Testers Cohort, which included some 1.3 million people screened for HCV in the province. The analysis focused on 5,702 people with HCV who were treated with direct-acting antivirals and who achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure) and had at least one subsequent measurement of their HCV RNA through April 2019.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.